These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16616803)

  • 21. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries.
    Cook J; Jeuland M; Whittington D; Poulos C; Clemens J; Sur D; Anh DD; Agtini M; Bhutta Z;
    Vaccine; 2008 Nov; 26(50):6305-16. PubMed ID: 18835415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent improvements in the Turkish Childhood National Immunization Program.
    Ceyhan M
    Turk J Pediatr; 2010; 52(6):563-9. PubMed ID: 21428186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The need for an evidence-based decision-making process with regard to control of hepatitis A.
    Gentile A
    J Viral Hepat; 2008 Oct; 15 Suppl 2():16-21. PubMed ID: 18837828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].
    van der Maas NA; David S; Kemmeren JM; Vermeer-de Bondt PE
    Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2732-7. PubMed ID: 18225797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost and cost-effectiveness of childhood vaccination against rotavirus in France.
    Melliez H; Levybruhl D; Boelle PY; Dervaux B; Baron S; Yazdanpanah Y
    Vaccine; 2008 Jan; 26(5):706-15. PubMed ID: 18166250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
    Jeuland M; Whittington D
    Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt.
    Ortega O; El-Sayed N; Sanders JW; Abd-Rabou Z; Antil L; Bresee J; Mansour A; Adib I; Nahkla I; Riddle MS
    J Infect Dis; 2009 Nov; 200 Suppl 1():S92-8. PubMed ID: 19817621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination vaccines: postlicensure safety evaluation.
    Chen RT; Pool V; Takahashi H; Weniger BG; Patel B
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S327-33. PubMed ID: 11709768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attitudes of nurses toward current and proposed vaccines for public programs: a questionnaire survey.
    Gilca V; Boulianne N; Dubé E; Sauvageau C; Ouakki M
    Int J Nurs Stud; 2009 Sep; 46(9):1219-35. PubMed ID: 19349047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the introduction of universal rotavirus vaccination in the Netherlands.
    Zomer TP; van Duynhoven YT; Mangen MJ; van der Maas NA; Vennema H; Boot H; de Melker HE
    Vaccine; 2008 Jul; 26(29-30):3757-64. PubMed ID: 18514975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current issues with the immunization program in Japan: can we fill the "vaccine gap"?
    Saitoh A; Okabe N
    Vaccine; 2012 Jul; 30(32):4752-6. PubMed ID: 22521841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program.
    Fowler GL; Baggs JM; Weintraub ES; Martin SW; McNeil MM; Gust DA
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):880-8. PubMed ID: 16924600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.
    Pickering LK; Baker CJ; Freed GL; Gall SA; Grogg SE; Poland GA; Rodewald LE; Schaffner W; Stinchfield P; Tan L; Zimmerman RK; Orenstein WA;
    Clin Infect Dis; 2009 Sep; 49(6):817-40. PubMed ID: 19659433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?
    Lopez AS; Guris D; Zimmerman L; Gladden L; Moore T; Haselow DT; Loparev VN; Schmid DS; Jumaan AO; Snow SL
    Pediatrics; 2006 Jun; 117(6):e1070-7. PubMed ID: 16740809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
    Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A deliberate choice? Exploring factors related to informed decision-making about childhood vaccination among acceptors, refusers, and partial acceptors.
    Romijnders KAGJ; van Seventer SL; Scheltema M; van Osch L; de Vries H; Mollema L
    Vaccine; 2019 Sep; 37(37):5637-5644. PubMed ID: 31383488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.